Evotec Achieves First Milestones in Multi-target Deal with UCB
News Oct 31, 2013
Evotec AG has announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology.
The milestones were achieved upon the progression of certain projects into hit-to-lead and into lead optimization.
Evotec and UCB entered into this collaboration in October 2011. Under the terms of the collaboration, Evotec receives research payments, milestones based on achieving various pre-clinical, clinical and sales goals and royalties on final product sales.
Dr Mario Polywka, Chief Operating Officer of Evotec, stated: 'We are delighted that the project teams at UCB and Evotec have met these important milestones in the collaboration. The progress in this collaboration is a testament to the way scientists from both companies have worked together in a true partnership.'
Dr Neil Weir, Senior Vice President of Discovery at UCB, commented that 'The collaboration with Evotec complements our internal research efforts and enhances our scientific network. Hitting these milestones is great news and as we continue to work together, we hope that the results will enhance the pace of the discovery process, the quality of compounds selected for further development and ultimately improve patient outcomes.'
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018